Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme

Diana My Frodi; Serge Boveda; Victor Fournier; Fawzi Kerkouri; Frederic Anselme; Jean-Claude Deharo; Fabrice Extramiana; Laurent Fauchier; Estelle Gandjbakhch; Daniel Gras; Alexis Hermida; Laurence Jesel-Morel; Christophe Leclercq; Nicolas Lellouche; Aymeric Menet; Kumar Narayanan; Olivier Piot; Vincent Probst; Nicolas Sadoul; Jerome Taieb; Pascal Defaye; Eloi Marijon; Rodrigue Garcia; behalf of the DAI-PP investigators

doi:10.1016/j.acvd.2024.10.335

Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme

Diana My Frodi
, Serge Boveda
, Victor Fournier
, Fawzi Kerkouri
, Frederic Anselme
, Jean-Claude Deharo
, Fabrice Extramiana
, Laurent Fauchier
, Estelle Gandjbakhch
, Daniel Gras
, Alexis Hermida
, Laurence Jesel-Morel
, Christophe Leclercq
, Nicolas Lellouche
, Aymeric Menet
, Kumar Narayanan
, Olivier Piot
, Vincent Probst
, Nicolas Sadoul
, Jerome Taieb

Pascal Defaye, Eloi Marijon, Rodrigue Garcia^*, behalf of the DAI-PP investigators

^*Corresponding author for this work

Department of Cardiology

2 Citations (Scopus)

Abstract

BACKGROUND: Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.

AIM: To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.

METHODS: Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002-2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).

RESULTS: This study included 9588 participants overall (DAI-PP Pilot Study, n=5539; DAI-PP Consortium, n=4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; P=0.001) and had a higher proportion of women (15.1% vs 20.6%; P<0.001), a similar proportion of ischaemic heart disease (60.2% vs 60.2%; P=0.98), a higher left ventricular ejection fraction (27±7% vs 30±8%; P<0.001) and more patients with narrow QRS complexes (30.5% vs 46.0%; P<0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1% vs 83.1%; P<0.001), whereas the use of amiodarone became much less frequent (22.7% vs 14.7%; P<0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8% vs 46.4%; P<0.001) and dual-chamber defibrillators (23.3% vs 17.3%; P<0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6%).

CONCLUSIONS: Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.

Original language	English
Journal	Archives of cardiovascular diseases
Volume	118
Issue number	3
Pages (from-to)	178-184
Number of pages	7
ISSN	1875-2128
DOIs	https://doi.org/10.1016/j.acvd.2024.10.335
Publication status	Published - Mar 2025

Keywords

Aged
Arrhythmias, Cardiac/therapy
Cardiac Resynchronization Therapy Devices/trends
Death, Sudden, Cardiac/prevention & control
Defibrillators, Implantable
Electric Countershock/instrumentation
Female
France/epidemiology
Humans
Male
Middle Aged
Pilot Projects
Primary Prevention/instrumentation
Prospective Studies
Prosthesis Design
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Implantable cardioverter defibrillator
Temporal trends
Sudden cardiac death
Baseline characteristics
Primary prevention

Access to Document

10.1016/j.acvd.2024.10.335

Cite this

Frodi, D. M., Boveda, S., Fournier, V., Kerkouri, F., Anselme, F., Deharo, J.-C., Extramiana, F., Fauchier, L., Gandjbakhch, E., Gras, D., Hermida, A., Jesel-Morel, L., Leclercq, C., Lellouche, N., Menet, A., Narayanan, K., Piot, O., Probst, V., Sadoul, N., ... behalf of the DAI-PP investigators (2025). Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme. Archives of cardiovascular diseases, 118(3), 178-184. https://doi.org/10.1016/j.acvd.2024.10.335

Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme. / Frodi, Diana My; Boveda, Serge; Fournier, Victor et al.
In: Archives of cardiovascular diseases, Vol. 118, No. 3, 03.2025, p. 178-184.

Research output: Contribution to journal › Journal article › Research › peer-review

Frodi, DM, Boveda, S, Fournier, V, Kerkouri, F, Anselme, F, Deharo, J-C, Extramiana, F, Fauchier, L, Gandjbakhch, E, Gras, D, Hermida, A, Jesel-Morel, L, Leclercq, C, Lellouche, N, Menet, A, Narayanan, K, Piot, O, Probst, V, Sadoul, N, Taieb, J, Defaye, P, Marijon, E, Garcia, R & behalf of the DAI-PP investigators 2025, 'Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme', Archives of cardiovascular diseases, vol. 118, no. 3, pp. 178-184. https://doi.org/10.1016/j.acvd.2024.10.335

@article{d7f12f99243a4ebdb63b54b4a1990cbc,

title = "Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme",

abstract = "BACKGROUND: Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.AIM: To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.METHODS: Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002-2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).RESULTS: This study included 9588 participants overall (DAI-PP Pilot Study, n=5539; DAI-PP Consortium, n=4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; P=0.001) and had a higher proportion of women (15.1\% vs 20.6\%; P<0.001), a similar proportion of ischaemic heart disease (60.2\% vs 60.2\%; P=0.98), a higher left ventricular ejection fraction (27±7\% vs 30±8\%; P<0.001) and more patients with narrow QRS complexes (30.5\% vs 46.0\%; P<0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1\% vs 83.1\%; P<0.001), whereas the use of amiodarone became much less frequent (22.7\% vs 14.7\%; P<0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8\% vs 46.4\%; P<0.001) and dual-chamber defibrillators (23.3\% vs 17.3\%; P<0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6\%).CONCLUSIONS: Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.",

keywords = "Aged, Arrhythmias, Cardiac/therapy, Cardiac Resynchronization Therapy Devices/trends, Death, Sudden, Cardiac/prevention \& control, Defibrillators, Implantable, Electric Countershock/instrumentation, Female, France/epidemiology, Humans, Male, Middle Aged, Pilot Projects, Primary Prevention/instrumentation, Prospective Studies, Prosthesis Design, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Implantable cardioverter defibrillator, Temporal trends, Sudden cardiac death, Baseline characteristics, Primary prevention",

author = "Frodi, \{Diana My\} and Serge Boveda and Victor Fournier and Fawzi Kerkouri and Frederic Anselme and Jean-Claude Deharo and Fabrice Extramiana and Laurent Fauchier and Estelle Gandjbakhch and Daniel Gras and Alexis Hermida and Laurence Jesel-Morel and Christophe Leclercq and Nicolas Lellouche and Aymeric Menet and Kumar Narayanan and Olivier Piot and Vincent Probst and Nicolas Sadoul and Jerome Taieb and Pascal Defaye and Eloi Marijon and Rodrigue Garcia and \{behalf of the DAI-PP investigators\}",

note = "Copyright {\textcopyright} 2025. Published by Elsevier Masson SAS.",

year = "2025",

month = mar,

doi = "10.1016/j.acvd.2024.10.335",

language = "English",

volume = "118",

pages = "178--184",

journal = "Archives of cardiovascular diseases",

issn = "1875-2128",

publisher = "Elsevier Masson",

number = "3",

}

TY - JOUR

T1 - Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients

T2 - The DAI-PP programme

AU - Frodi, Diana My

AU - Boveda, Serge

AU - Fournier, Victor

AU - Kerkouri, Fawzi

AU - Anselme, Frederic

AU - Deharo, Jean-Claude

AU - Extramiana, Fabrice

AU - Fauchier, Laurent

AU - Gandjbakhch, Estelle

AU - Gras, Daniel

AU - Hermida, Alexis

AU - Jesel-Morel, Laurence

AU - Leclercq, Christophe

AU - Lellouche, Nicolas

AU - Menet, Aymeric

AU - Narayanan, Kumar

AU - Piot, Olivier

AU - Probst, Vincent

AU - Sadoul, Nicolas

AU - Taieb, Jerome

AU - Defaye, Pascal

AU - Marijon, Eloi

AU - Garcia, Rodrigue

AU - behalf of the DAI-PP investigators

PY - 2025/3

Y1 - 2025/3

N2 - BACKGROUND: Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.AIM: To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.METHODS: Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002-2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).RESULTS: This study included 9588 participants overall (DAI-PP Pilot Study, n=5539; DAI-PP Consortium, n=4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; P=0.001) and had a higher proportion of women (15.1% vs 20.6%; P<0.001), a similar proportion of ischaemic heart disease (60.2% vs 60.2%; P=0.98), a higher left ventricular ejection fraction (27±7% vs 30±8%; P<0.001) and more patients with narrow QRS complexes (30.5% vs 46.0%; P<0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1% vs 83.1%; P<0.001), whereas the use of amiodarone became much less frequent (22.7% vs 14.7%; P<0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8% vs 46.4%; P<0.001) and dual-chamber defibrillators (23.3% vs 17.3%; P<0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6%).CONCLUSIONS: Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.

AB - BACKGROUND: Patient characteristics, technology and clinical practice surrounding primary prevention implantable cardioverter defibrillators have evolved continuously over time.AIM: To explore the temporal changes in patient characteristics, pharmacological therapy and device types among implantable cardioverter defibrillator recipients implanted for the primary prevention of sudden cardiac death over the last two decades in France.METHODS: Characteristics of participants and type of device from the retrospective DAI-PP Pilot Study (2002-2012) were compared with those from the ongoing prospective DAI-PP Consortium (2018 onwards).RESULTS: This study included 9588 participants overall (DAI-PP Pilot Study, n=5539; DAI-PP Consortium, n=4049). Compared with the DAI-PP Pilot Study, the DAI-PP Consortium subjects were older at implantation (62.5 vs 65.2 years; P=0.001) and had a higher proportion of women (15.1% vs 20.6%; P<0.001), a similar proportion of ischaemic heart disease (60.2% vs 60.2%; P=0.98), a higher left ventricular ejection fraction (27±7% vs 30±8%; P<0.001) and more patients with narrow QRS complexes (30.5% vs 46.0%; P<0.001). The proportion of patients treated with heart failure drugs increased significantly (70.1% vs 83.1%; P<0.001), whereas the use of amiodarone became much less frequent (22.7% vs 14.7%; P<0.001). Finally, the proportions of cardiac resynchronization therapy defibrillators (53.8% vs 46.4%; P<0.001) and dual-chamber defibrillators (23.3% vs 17.3%; P<0.001) decreased, whereas subcutaneous implantable cardioverter defibrillators now account for a sizeable proportion of implants (14.6%).CONCLUSIONS: Over a 20-year period, the primary prevention implantable cardioverter defibrillator population has evolved significantly, with an older age and a higher proportion of women. The type of device has changed, with fewer cardiac resynchronization therapy defibrillators and more subcutaneous implantable cardioverter defibrillators.

KW - Aged

KW - Arrhythmias, Cardiac/therapy

KW - Cardiac Resynchronization Therapy Devices/trends

KW - Death, Sudden, Cardiac/prevention & control

KW - Defibrillators, Implantable

KW - Electric Countershock/instrumentation

KW - Female

KW - France/epidemiology

KW - Humans

KW - Male

KW - Middle Aged

KW - Pilot Projects

KW - Primary Prevention/instrumentation

KW - Prospective Studies

KW - Prosthesis Design

KW - Retrospective Studies

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Implantable cardioverter defibrillator

KW - Temporal trends

KW - Sudden cardiac death

KW - Baseline characteristics

KW - Primary prevention

UR - https://www.scopus.com/pages/publications/85216685703

U2 - 10.1016/j.acvd.2024.10.335

DO - 10.1016/j.acvd.2024.10.335

M3 - Journal article

C2 - 39890483

SN - 1875-2128

VL - 118

SP - 178

EP - 184

JO - Archives of cardiovascular diseases

JF - Archives of cardiovascular diseases

IS - 3

ER -

Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this